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ABSTRACT 
The T-cell mediated adaptive immune response is important in controlling infection with 
Mycobacterium tuberculosis (M.tb). Several types of T-cells participate in the anti-M.tb 
defense, including CD4+ and CD8+ cells. CD8+ T-cells recognize small parts, so-called 
epitopes, of foreign antigens as well as self-derived antigens in association with MHC class I 
molecules. Identification of T-cell epitopes might therefore aid in the development of 
diagnostic markers and vaccine candidates. They may also guide to monitor CD8+ T-cell 
responses in disease settings where CD8+ T-cells play a role in biologically and clinically 
relevant immune responses. 
 
In this thesis, we evaluated the previously identified M.tb-derived T-cell epitopes (Paper V), as 
well as identified novel M.tb-derived CD8+ T-cell epitopes from several proteins (TB10.4, 
Ag85B, ESAT-6, glycosyl transferase I, glycosyl transferase 2 and cyclopropane fatty acid 
synthase) (Papers I–III). The epitopes were restricted by a wide range of MHC class I 
allotypes, including some of the most common alleles in Caucasian, Asian and African 
population groups. Most of the MHC class I alleles common in the African groups were not 
commercially available. Therefore, they were cloned and subsequently expressed as 
recombinant proteins in order to be used in peptide binding detection and to construct peptide-
MHC class I multimeric complexes for the first time (Papers II–III).  
 
We studied peptide-MHC interactions to 13 different allotypes by using overlapping peptide 
libraries. A variable broadness of peptide binding patterns was identified. Some alleles showed 
a diverse pattern, allowing binding of many epitopes, while others displayed a more restricted 
peptide binding pattern. Another interesting feature was the very frequent occurrence of 
promiscuous binding epitopes. Subsequent evaluation of the binding characteristics of a 
majority of the 672 identified binding epitopes showed a wide range of affinities and 
dissociation rates with both inter- and intra-allelic differences (Papers I–III).  
 
An extensive panel of 62 MHC class I multimers was constructed in order to validate some of 
the previously identified binding epitopes as being CD8+ T-cell epitopes. We also used these 
reagents to characterize M.tb-specific CD8+ T-cell responses in patients with pulmonary 
tuberculosis (TB) with diverse ethnic background (Caucasian, Asian and African). Generally, a 
low CD8+ T-cell response reflecting a diverse M.tb-specific reactivity could be detected, with 
only a few immunodominant epitopes. The majority of the M.tb-specific CD8+ T-cells had a 
precursor-like phenotype (CD45RA+CCR7+), despite expressing high frequencies of the 
degranulation marker CD107a, indicating that antigen-experienced effector cells reside in this 
population (Papers II–IV). One explanation for the high number of specific ‘naïve-like’ T-cells 
might be that they belong to a compartment of memory cells with ‘stem-cell like’ features, 
including expression of c-kit (CD117) and CD95 (Paper IV).  
 
This thesis shows that both MHC class I allotypes and epitope-derived proteins might influence 
immune recognition on several levels including peptide-MHC binding, T-cell receptor (TCR) 
engagement as well as T-cell effector functionality and phenotype of the antigen-specific T-
cells (Paper III); The T-cell phenotype and M.tb-specific T-cell frequency appear to be 
determined by both the restricting allele and the antigen. 
 
In conclusion, we identified and validated many novel CD8+ T-cell targets from M.tb-derived 
proteins restricted via a broad range of MHC class I molecules, with the hope that these tools 
will aid future diagnostics and prevention strategies in different disease settings. 
  
SAMMANFATTNING PÅ SVENSKA 
Det T-cellsförmedlade adaptiva immunförsvaret är viktigt för att hålla en infektion med 
Mycobacterium tuberculosis (M.tb) under kontroll. Flera olika typer av T-celler, t.ex. CD4+ och 
CD8+, ingår i vårt immunförsvar mot tuberkulos (TBC). CD8+ T-celler känner igen små delar, 
så kallade epitoper, av främmande antigen eller proteiner härledda från egna kroppen, bundna 
till MHC klass I-molekyler. Identifiering av T-cellsepitoper kan därför hjälpa till vid 
utvecklandet av nya diagnostiska markörer och vaccinkandidater. De kan också hjälpa till att 
övervaka CD8+ T-cellssvar vid sjukdomstillstånd där CD8+ T-celler har betydelse för 
immunförsvaret, både biologiskt och kliniskt. 
 
I denna avhandling har vi utvärderat tidigare identifierade epitoper härledda från M.tb-proteiner 
(delarbete V) samt identifierat nya CD8+ T-cellsepitoper härledda från M.tb-proteiner (TB10.4, 
Ag85B, ESAT-6, glykosyltransferas I, glykosyltranferas 2 och cyklopropan-fettsyra-syntas) 
(delarbete I–III). Epitoperna presenterades av många olika MHC klass I-alleler, inklusive några 
av de mest vanliga allelerna i kaukasiska, asiatiska och afrikanska befolkningsgrupper. På 
grund av att de flesta MHC klass I-alleler som är vanliga i afrikanska befolkningsgrupper inte 
finns att få tag på kommersiellt, klonade och konstruerade vi dem själva för första gången och 
använde dem för att detektera peptidbinding och för att konstuera peptid-MHC- 
multimerkomplex (delarbete II–III). 
 
Vi studerade peptid-MHC-bindning till 13 olika MHC klass I-alleler genom att använda 
överlappande peptidbibliotek. Variationer i bredden på peptidbindningen kunde identifieras. 
Vissa alleler hade ett brett bindningsmönster som tillät bindning av många vitt skilda epitoper, 
medan andra alleler uppvisade ett mer begränsat peptidbindingsmönster. En annan intressant 
upptäckt var vanligt förekommande korsbinding av epitoper mellan olika MHC klass I-alleler. 
Efterföljande analys av bindningsegenskaperna hos en majoritet av de 672 identifierade 
bindningsepitoperna visade ett brett intervall av affiniteter och dissociationshastigheter som 
varierade både inom och mellan olika alleler (delarbete I–III). 
 
En omfattande panel bestående av 62 MHC klass I-multimerer konstruerades för att bekräfta att 
några av de sedan tidigare identifierade bindningsepitoperna var CD8+ T-cellsepitoper. Vi 
använde också dessa reagenser för att karakterisera det M.tb-specifika CD8+ T-cellssvaret i 
patienter med lung-TBC från olika etniska befolkningsgrupper (kaukasiska, asiatiska och 
afrikanska). Generellt sett kunde ett lågt men brett M.tb-specifikt CD8+ T-cellssvar detekteras, 
med enbart ett fåtal immunodominanta epitoper. Majoriteten av de M.tb-specifika CD8+ T-
cellerna hade en naiv fenotyp (CD45RA+CCR7+), trots att de uttryckte höga frekvenser av 
degranuleringsmarkören CD107a, vilket indikerar att antigen-erfarna effektorceller finns i 
denna population (delarbete II–IV). En förklaring till de höga frekvenserna av antigenspecifika 
celler med naiv fenotyp kan vara att de tillhör en grupp minnesceller med stamcellslika 
egenskaper t.ex. uttryck av ytmarkörerna c-kit (CD117) och CD95 (delarbete IV). 
 
Denna avhandling visar vidare att både de presenterande MHC klass I-allelerna och de 
proteiner som epitoperna kan härledas ifrån kan påverka immunförsvarets igenkänning på flera 
nivåer såsom peptid-MHC-bindning, igenkänning via T-cellsreceptorer samt effektorfunktion-
alitet och fenotyp av de antigenspecifika T-cellerna (delarbete III); T-cellernas fenotyp och 
antalet M.tb-specifika T-celler verkar påverkas av både den presenterande MHC-allelen och av 
den tuberkuloshärledda antigenen.  
 
Sammanfattningsvis har vi identifierat och validerat många nya CD8+ T-cellseepitoper 
härledda från M.tb-proteiner och presenterade via många olika MHC klass I-molekyler, med 
förhoppning om att dessa ska hjälpa till i utvecklingen av nya diagnostiska metoder och 
förebyggande åtgärder för flertalet sjukdomar i framtiden.  
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1 INTRODUCTION 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(M.tb). The bacterium has infected humans for more than 4 000 years, yet there were 
still 8.8 million new cases of TB, and 1.45 million deaths reported in 2010. Although 
the highest number of cases can be found in south-east Asia, the highest incident by far 
can be found in sub-Saharan Africa (Figure 1) [1]. Factors contributing to the epidemic 
include inadequate vaccine efficacy, inadequate diagnostics [2] as well as drug 
resistance and the human immunodeficiency virus (HIV) epidemic [3]. Therefore, more 
information about what constitutes and regulates protective immunity in TB needs to be 
gained.  
The cell-mediated adaptive immune response is important in controlling M.tb 
infections. An effective anti-M.tb response has been shown to be mainly cell-mediated, 
with different compartments of T-cells: CD4+ and CD8+ [4, 5] yet NK-cells [6], NK-
T-cells [7] and γδ-T-cells [8], also play an important role at different stages of the 
infection. T-cells recognize, and are activated by, small parts (so-called epitopes) of 
protein-derived antigens presented via major histocompatibility complex (MHC) 
glycoproteins. Identification of epitopes is highly valuable in diagnostics as well as for 
the development of novel vaccine regiments and for gauging of vaccine take. Although 
 
Figure 1. Estimated TB incidence rates 2010. 
Source: World Health Organization (WHO) [1].
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the CD4+ T-cell response is more well-studied, previous studies have shown that 
cytotoxic CD8+ T-cells are important in the defense against TB [5] and that they are 
induced early in the infection [9]. Identification of novel antigenic peptides recognized 
by CD8+ T-cells presented via the MHC class I complex, will therefore be of great 
value to better understand the cytotoxic T-lymphocyte (CTL)-mediated anti-M.tb 
immune response. 
 
1.1 IMMUNOLOGY 
1.1.1 Major histocompatibility complex (MHC) 
The MHC multigene cluster contains more than 200 genes. In humans, this cluster is 
called human leukocyte antigen (HLA), since the proteins were first discovered as 
transplantation antigens that varied among individual patients. The gene family is 
divided into three sub-groups (class I, II and III). The first two classes (class I and II) 
encode glycoprotein receptors involved in antigen-presentation of protein-derived 
antigens towards T-cells (MHC class I and II molecules) as well as antigen processing 
molecules and proteins involved in peptide loading such as transporter associated with 
antigen processing (TAP) and tapasin. The class III gene family encodes other proteins 
involved in the immune system, such as complement components (e.g. C4, C2 and 
factor B) and cytokines (e.g. tumor necrosis factor-α and lymphotoxin) [10].  
 
The classical MHC class I molecules, HLA-A, -B and -C (non-classical: e.g. HLA-E, 
-F and -G) are encoded by three loci located on chromosome 6 in humans and they 
present predominantly endogenously derived antigens to CD8+ T-cells. MHC class II 
molecules are subdivided into HLA-DP, DQ and DR (non-classical HLA-DM and 
-DO) and present mainly exogenous antigens toward CD4+ T-cells (T-helper [Th] 
cells). Exogenously derived peptides might also be presented via MHC class I 
molecules via cross-presentation [11, 12]. MHC class I molecules are expressed at 
different levels on all nucleated cells, while MHC class II molecules are only expressed 
on specific antigen-presenting cells (APCs) such as dendritic cells (DCs), macrophages 
and B-cells. The glycoproteins are not only important for antigen-presentation, but also 
for self-recognition.  
 
1.1.1.1 Diversity of the MHC class I 
The MHC class I glycoprotein is the most polymorphic molecule in the human body, 
with more than 5 000 different versions (alleles) identified. The individual MHC class I 
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alleles can differ by up to 20 amino 
acids, making each variant unique. 
The HLA-B locus is the most 
diverse with more than 2 000 
different alleles, followed by HLA-
A (~1 700) and HLA-C (~1 300) 
(Figure 2) [13]. Each individual 
can carry and co-dominantly 
express up to six different alleles, 
since in addition to being poly-
morphic the molecules are also 
polygenic, with each chromosome 
containing one HLA-A, one HLA-
B and one HLA-C allele. Both haplotypes (allele-combinations found on a 
chromosome) are subsequently co-dominantly produced and expressed on the cell-
surface. 
Table 1. 
Average frequencies (%) of a number of selected MHC class I alleles for different population groups. 
Adapted from numbers derived from the Allele frequency net database [14]. 
 
Allele Caucasians Asians Africans 
A*01:01 12 4 4 
A*02:01 25 7 9 
A*03:01 13 3 5 
A*11:01 6 18 1 
A*24:02 10 19 3 
A*30:01 1 3 6 
A*30:02 1 1 7 
A*68:01 3 2 3 
B*07:02 10 2 5 
B*08:01 8 1 4 
B*15:01 5 3 1 
B*58:01 2 7 5 
C*07:01 14 4 17 
 
The frequencies of many alleles are evenly distributed between different population 
groups (e.g. A*68:01 and B*58:01). However, different distribution of MHC class I 
alleles can be found based on geographic location or ethnicity for most of the MHC 
class I alleles (e.g. A*02:01, A*11:01 and A*30:02) [14] (Table 1).  
 
Figure 2. Number of MHC class I alleles for the 
different HLA loci.  
Adapted from numbers derived from IMGT/HLA database 
[13]. 
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1.1.1.2 Structure of the MHC class I glycoprotein 
The MHC class I glycoprotein consists of an invariant 12 kDa light chain (96 amino 
acids) (β2-microglobulin [β2m]) encoded outside the HLA-locus (on chromosome 15), 
non-covalently linked to a 43 kDa 
(340 amino acids) membrane 
anchored polymorphic heavy chain. 
The heavy chain consists of three 
sub-domains (α1, α2 and α3), of 
which the first two form the walls 
and bottom of the peptide binding 
cleft and the third ends in the 
transmembrane region anchoring the 
molecule to the cell-membrane, as 
well as containing a short cyto-
plasmic tail. A protein-derived 
peptide fragment, usually between 8 
and 10 amino acids long, constitutes 
the third part of the trimeric complex 
(Figure 3). Without the peptide, the 
trimeric complex remains unstable 
and the molecules will rapidly 
dissociate [15]. 
 
1.1.1.3 The peptide binding cleft and the peptide motif 
Two α-helixes, forming the walls on top of an antiparallel 8-stranded β-sheet forming 
the floor, create the peptide binding cleft of an MHC class I molecule. The cleft is 
closed at the ends by certain inter-allelic conserved tyrosine residues which interact 
with the amino and carboxy terminal ends of the presented peptide, limiting, in most 
of the cases, the size of binding peptides to 8–10 amino acids [16]. The peptides bind 
in an elongated conformation within the cleft and ‘kinking’ of the peptides explains 
peptide binding of additional length associated with some MHC class I alleles, e.g. 
HLA-35 [17]. Most of the polymorphism that defines the different MHC class I alleles, 
lies within the peptide binding clefts and, more specifically, within amino acid residues 
interacting directly with the peptide [18]. These residues form 6 binding pockets 
labeled A–F, that interact with specific amino acids positions within a potential peptide 
β
2
m 
α
1
 
 
Figure 3. Structure of the peptide-β2m-MHC class I 
complex. 
Adapted from PDB file 1AKJ [49].
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(Figure 4) [19, 20], thereby allowing each individual MHC class I allele to bind a large 
repertoire of peptides that varies inter-allelic. Each MHC class I allele will therefore 
only accommodate a certain repertoire of peptides with properties (electrostatic, 
hydrophobicity or bulki-
ness) that match the 
specific biochemical en-
vironments within these 6 
binding pockets. Some 
positions within the 
peptide are more important 
for interaction with the 
MHC molecule than 
others; they are called 
‘anchor residues’. Anchor 
residues are therefore often 
conserved. They are 
usually situated at position 
two (P2) and at the 
carboxy-terminal (P9) end of a peptide interacting with pocket B and F. Yet, inter-
allelic variations exist with some alleles preferring peptides with anchor-residues at 
position 3 (P3) and C-terminus (P9) (e.g. HLA-A*01), or only at the C-terminal end 
(P9) (e.g. HLA-A*11:01 and A*31:01) [21]. However, these anchor residues are not 
sufficient for high-affinity binding, since not all peptides with suitable anchor residues 
bind to the respective MHC molecule. In addition, most alleles show auxiliary (or 
secondary) anchor residues critical or important for peptide binding. In the case of 
HLA-A*02:01 (one of the most well-studied human MHC class I molecules), the 
anchor residues have been described to be either leucine or methionine at P2 in the 
binding peptide and either valine or leucine at P9 [22]. In addition, the amino acid 
situated at P3 in the presenting peptide has been shown to be a secondary anchor 
residue [23]. Altogether, the primary and auxiliary anchor residues form the allele-
specific peptide motif. The motif is not absolute, as numerous peptides without the 
appropriate primary and auxiliary anchor residues have been identified as well as 
longer [24] or shorter peptides [25]. However, by using the sequence motif one can 
accurately predict peptide binding, at least for the more well-studied MHC class I 
alleles [21, 26, 27]. 
Figure 4. The peptide binding cleft of a MHC class I molecule, 
including the peptide binding pockets A-F. 
Adapted from PDB file 1AKJ [49] .
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1.1.1.4 Antigen processing and antigen-presentation 
The correct assembly and folding of the heavy chain of the MHC class I molecules take 
place in the endoplasmic reticulum (ER). This step is stabilized by the chaperon 
calnexin and is followed by incorporation of β2m and the formation of the peptide-
loading complex (PLC). The PLC is composed of two MHC-encoded components, 
TAP and tapasin, as 
well as two ‘house-
keeping’ ER proteins, 
calreticulin and ERp57 
[28]. They help in 
loading a broad range 
of high-affinity pep-
tides into the peptide 
binding clefts of the 
MHC class I molecules 
[29]. 
 
In the direct antigen 
processing pathway, 
endogenous peptides, 
i.e. ‘self’, viral or 
bacterial proteins form-
ed in the cytosol of the 
cell, are presented on 
MHC class I glyco-
proteins. Misfolded or 
foreign proteins are first tagged for destruction by ubiquitylation. Ubiquitinated 
proteins are then degraded in the proteasome and the peptides formed are transported 
to the ER via the ATP-dependant dimeric TAP-transporter system [30] before they 
are occasionally additionally trimmed by aminopeptidases [31]. In the ER, peptides of 
the approximate length of 8–10 amino acids bind to the MHC class I molecules and 
the trimeric complex is transported via the secretory pathway through the Golgi 
apparatus to the cell-surface. The peptides are subsequently presented to CD8+ T-
cells on the cell-surface [32] (Figure 5A).  
A 
B 
Figure 5. (A) The classical antigen presenting pathway and (B) 
pathways for cross-presentation of exogenously generated peptides. 
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Signal sequences of proteins, designated for the cell-surface, are cleaved off in the ER 
and peptides originating from them can be loaded directly in the ER, independently of 
the TAP transport [33]. Retrograde translocation of ER-associated proteins back to 
the cytosol is another mechanism for endogenous peptide generation [34].  
 
Exogenously generated peptides, e.g. most bacterial proteins, induce predominantly 
B-cell (humoral) and CD4+ T-cell responses; by recognition of the nominal antibody 
molecule and MHC class II restricted presentation respectively. Exogenously derived 
antigens can, via different pathways, also associate with MHC class I molecules, a 
phenomenon referred to as ‘cross-presentation’ [35]. In most cases, the peptides 
originate from intra-cellular pathogens escaping to the cytosol, phagocytosed 
pathogens or from phagocytosed apoptotic bodies. After uptake by e.g. DCs or 
macrophages, the proteins are retranslocated to the cytosol, cleaved by the 
proteasome and delivered to the ER, similar to the classical pathway (TAP-dependant 
pathway) [36]. Cytosolic access occurs either via leakage, pore formation, active 
transport through the vacuolar membrane, or via direct fusion of the vacuole to the 
ER. An alternative way of cross-presentation occurs when MHC class I molecules 
take up and present phagosome and vacuolar-degraded antigens directly within the 
vacuolar system [37, 38] (TAP-independent pathway) (Figure 5B). 
  
1.1.1.5 Epitopes 
An antigenic determinant, ‘epitope’, is the part of an antigen that the adaptive immune 
system (mainly T-cells and B-cells) recognizes. CD8+ T-cell epitopes consist of 
peptides bound to MHC class I molecules recognized by the T-cell receptor (TCR). The 
immunogenicity of an epitope depends on several criteria; 1) the epitope must be 
generated and transported to the endoplasmic reticulum, by overcoming limitations in 
proteasome dependent proteolysis [39] and restrictions related to the TAP-system [40] 
or by cross-presentation [41], 2) the epitope must bind to the MHC haplotype with 
appropriate affinity and dissociation rate, 3) the peptide-MHC complex must then be 
recognized by the individual’s specific TCR repertoire and subsequent trigger T-
lymphocytes. 
 
Different strategies could be utilized for identification of CD8+ T-cell epitopes. Either 
one could start with identification of a positive T-cell response (e.g. by measuring 
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proliferation or cytokine production) and then track down the specific epitope. The 
opposite strategy could be utilized as well, starting with the identification of MHC-
binding peptides from an immunogenic protein (using e.g. in silico selected or 
overlapping peptide libraries and recombinant MHC molecules  or T-cell stabilization 
assays [42, 43]) followed by assessing the ability of these epitopes to elicit a T-cell 
response, e.g. by using MHC-multimers [44], or functional assays (e.g. enzyme-linked 
immunosorbent assay [ELISA], enzyme-linked immunosorbent spot [ELISPOT], intra-
cellular cytokine staining [ICS] or cytotoxicity assays). By utilizing these methods, a 
high number of CD4+ and CD8+ T-cell epitopes have been identified in many different 
disease settings. However, we still lack knowledge of T-cell epitope identification in 
many areas. For instance, knowledge of the exact restricting MHC allele is frequently 
missing or, if it is known, one can detect a clear bias towards epitopes presented on a 
limited number of well-studied ‘Caucasian’ MHC class I alleles such as HLA-A*02:01, 
A*03:01, A*11:01 and B*15:01 [45].  
 
1.1.2 T-cells  
T-cells are differentiated in the thymus from bone-marrow-derived common lymphoid 
progenitor cells. During this differentiation process, thymocytes undergo a series of 
defined maturation steps, including that each progenitor T-cell makes its own specific 
TCR by gene rearrangement. To create a self-tolerant T-cell repertoire which is able to 
recognize foreign antigens, T-cell clones carrying TCRs that recognize MHC molecules 
too weakly or self-antigens (too strongly) are subsequently deleted via positive and 
negative selection, respectively. Thereafter, the thymocytes are committed to either 
CD4 or CD8 linage before entering the circulation as mature T-cells. Upon antigenic 
encounter, naïve non-antigen-experienced T-cells need to be primed against their 
cognate antigen by APCs, before becoming competent effector cells as well as long-
lived memory T-cells. Antigenic encounter is mediated via the TCR which recognizes 
only antigens in association with an individual’s own MHC molecules, the ‘MHC 
restriction’ [46].  
 
1.1.2.1 The T-cell receptor  
In most T-cells, the TCR is a heterodimer composed of disulfide-linked α and β 
polypeptide chains (a minority of T-cells, so-called γδ-T-cells, uses γ and δ 
polypeptide chains instead), each having separate constant and variable domains. The 
constant domains of the TCR are anchored in the cell-membrane of the T-cell. Each 
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variable region of the TCR is assembled from a number of randomly selected gene 
segments called V, D and J, at the junctions of these segments additional diversity is 
introduced through imprecise joining thereby creating a large repertoire of putative 
TCRs. In addition, the variable domain contains three hypervariable regions or 
complementary determining regions (CDRs) that are responsible for antigen 
recognition. The CDR1s interact predominantly with the N and C terminal ends of the 
peptide; the CDR2s interact with the α-helixes of the MHC molecules and the 
CDR3s, which are the most hypervariable loops, interact with the central part of the 
presented peptide [47].  
 
1.1.2.2 CD8 co-receptor 
Another cell-surface glycoprotein that is present on the cell-surface of certain T-cells 
(CD8+ T-cells), as well as on other immune cells (e.g. natural killer cells and dendritic 
cells), is the CD8 molecule. In most cases, CD8 represents a heavily glycosylated 
disulfide-linked heterodimer consisting of an α- and a β-chain, but a homodimer 
consisting of two α-chains is expressed on a certain subset of T-cells (αα T-cells). On 
T-cells, CD8 serves as a co-receptor for the TCR by recruiting essential intracellular 
signaling molecules, e.g. Lck [48] to the TCR complex, as well as interacting with the 
constant regions of the α2 and α3 domains of the peptide-MHC complex [49, 50]. The 
interaction keeps the TCR of the CD8+ T-cell and the target cell bound closely 
together, thereby allowing for prolonged engagement. During antigen-specific 
activation, this is thought to increase the sensitivity of a T-cell to its antigen a 
hundredfold.  
 
1.1.3 MHC-TCR interaction 
Both CD8+ T-cell priming and target recognition of T-cells in the effector phase of 
the immune response are dependent on MHC-TCR interactions. T-cell priming needs 
a variety of receptor-associated signaling events to take place between the T-cell and 
the APC, including the formation of the peptide-MHC-TCR complex (signal 1), co-
stimulatory signaling (B7-1/B7-2 and CD28) (signal 2) as well as cytokine signaling 
(e.g. interleukin-12 [IL-12]) [51] (signal 3), while effector cells can respond to their 
target cells without co-stimulatory signals [52]. The frequency of individual peptide-
MHC complexes on the cell-surface of infected cells is thought to be very low; only a 
few (10–50) TCR-MHC interactions are thought to be needed for T-cell activation, 
and even less for subsequent CD8+ T-cell mediated cytotoxicity [53]. 
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1.1.3.1 The immunological synapse  
The initial contact between APC and naïve T-cells is mediated by cell-adhesion 
molecules like intracellular adhesion molecules (ICAMs) [54]. The binding between an 
individual MHC molecule and a TCR is characterized by low affinity and fast 
dissociation rate, which is required for enabling serial contacts of each TCR molecule 
to bind to multiple MHC-peptide ligands [55]. The interaction between the TCR and 
the peptide-MHC complex is a two-step process. In the first step, the TCR docks on 
the MHC molecule in a peptide-independent fashion. This is followed by contact 
between the TCR and the peptide, which stabilizes or abrogates the MHC-TCR 
complex [56]. The TCR orients itself diagonally across the peptide-MHC complex, 
with the TCRα-chain lying above the amino-terminal end of the bound peptide and 
the α2 domain of the MHC class I molecule and the TCRβ-chain interacting with the 
carboxy terminal end and the α1 domain. Certain residues within the TCRs loops then 
interact with individual protuberating residues on the MHC complex, small 
alterations within the peptide might consequently alter the T-cell response. Because 
of this, it is believed that certain variable TCR genes have co-evolved with certain 
MHC alleles [57].  
 
1.1.3.2 Immunodominance 
The immune recognition by antigen-specific CD8+ T-cells in many diseases is often 
directed against a few of the many potential epitopes originating from a complex 
pathogen. This ‘skewing’ of the immune system gives rise to immunodominant 
epitopes, which might be accompanied by less recognized sub-dominant epitopes [58]. 
The driving force behind immunodominance and sub-dominance in different disease 
settings is not completely elucidated, but factors that are considered crucial include 1) 
availability (time and receptor numbers) of the peptide-MHC complex on the cell-
surface [59], 2) the stability and the conformation of the presented epitope [17] and 3) 
the frequencies of T-cell precursors with the possibility of recognizing the epitope [60]. 
Recognition of certain epitopes might as well dampen the immune recognition of other 
epitopes, a process called ‘immunodomination’.  
 
1.1.4 Phenotype and effector functions of T-cells 
Before activation, naïve CD8+ T-cells are immunologically pluripotent with the 
possibility to differentiate either into effector or memory subsets upon activation [61]. 
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Therefore, the degree and time of antigenic stimulation, cytokine availability, co-
stimulatory environment and the presence of CD4+ T-cell help are important factors for 
complete activation to occur as well as for determining the fate of a precursor CD8+ T-
cell [51, 62]. Initially during infections, a massive heterogeneous response of antigen-
specific T-cells is elicited. Only a small percentage of these initially clonally expanded 
cells survive and proceed to long-lived heterogeneous memory subsets after clearance 
of the pathogen. 
  
1.1.4.1 T-cell phenotypic compartments 
Based on a number of cell-surface markers such as CD45RA and CCR7, mature CD8+ 
T-cells can be divided into four different phenotypic compartments [63, 64]. CD45RA 
is an isoform of the protein tyrosine phosphatase receptor type C and functions as a 
regulator of receptor signaling in T-cells and B-cells, while CCR7 (CD197) is a 
chemokine receptor responsible for migration of naïve and central memory 
lymphocytes to secondary lymphoid organs. Antigen non-experienced precursor T-cells 
express both markers on their cell-surface and are able to give rise to memory or 
effector T-cells upon antigen encounter. There are two different compartments of 
memory T-cells based on expression of the chemokine receptor CCR7. Central memory 
T-cells express this receptor, but have switched the expression of the CD45RA isoform 
to another isoform (CD45RO). They are lymph-node homing antigen-experienced cells 
with high proliferative capacity, and are believed to lack immediate effector functions 
(except IL-2 production) and upon rechallenge need co-stimulation in order to expand. 
The other memory compartment consists of effector memory T-cells, which have 
down-regulated both cell-surface markers and exhibit a high degree of effector 
functionality, low proliferation rate and preferentially reside as sentinels in tissues. 
Terminally differentiated effector cells (TEMRA) (CD45RA+CCR7-), which home to 
disease sites, constitute the last and most differentiated compartment. They are mainly 
effector cells with limited proliferating capacity [65].  
 
1.1.4.2 CD8+ T-cell effector functions  
T-cells produce two main classes of effector functions: cytotoxins and cytokines. CD8+ 
T-cells are called cytotoxic T-cells based on their main effector functions, i.e. cytolytic 
killing of infected cells by the help of cytotoxic granules containing cytotoxins (e.g. 
perforin, granzyme and granulysin). Perforin makes contact with the target cell and 
helps to release granzyme to the cytoplasm where the protease is activated to induce 
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apoptosis in the target cell [66]. However, many CD8+ T-cells also carry the Fas-ligand 
(CD178) by which they might induce apoptosis in Fas receptor (CD95/APO-1) 
expressing cells. A third effector function of the cells is cytokine production, for 
example interferon-γ (IFN-γ), IL-2 and TNF-α. IL-2, IFN-γ and TNF-α have a central 
role in the cellular immunity; IFN-γ is for example important for activation and 
differentiation of immune cells as well as up-regulation of MHC molecules and TNF-α 
is an important activating cytokine for macrophages and endothelial cells.  
 
Upon chronic infection, dysfunctional T-cells might arise. They are either characterized 
by the loss of proliferative capacity, due to telomere erosion or DNA damage 
(senescence) or characterized by expression of inhibitory receptors and an altered 
transcriptional profile associated with compromised effector functions (T-cell 
exhaustion). T-cell exhaustion is associated with high antigenic load and the exhausted 
cells most often display an effector memory phenotype characterized by the up-
regulation of inhibitory receptors such as programmed death 1 (PD1) receptor, 
cytotoxic T-lymphocyte antigen 4 (CTLA4) and lymphocyte activation gen 3 (LAG3) 
[67]. The effector functionality of these cells might become compromised starting with 
a decreased IL-2 production, followed by TNF-α production, decreased cytotoxic 
activity and finally a loss of IFN-γ production. This might occur generally, or more 
specifically in certain antigen-specific T-cell clones [68, 69].  
 
1.1.4.3 Other cell-surface markers 
Evaluation of cytotoxic effector functions of CD8+ T-cells can be done without 
measuring the intracellular cytolytic molecules themselves, by enumerating the 
frequencies of cells expressing CD107a (LAMP-1) on the cell-surface. CD107a is 
associated with the membrane of cytolytic granules carrying perforin and granzyme, 
and this marker can be measured on the cell-surface of T-cells upon exocytosis of these 
vesicles [70]. The measurements can be done either in ex vivo assays (which reflect the 
activation of immune cells without in vitro manipulation) [71] or, alternatively, after 
antigenic stimulation in vitro. 
 
The cytokine IL-7 is important for T-cell homeostasis, growth, maturation and memory 
formation [72]. It acts by signaling through the IL-7R, which is a heterodimer 
composed of the IL-7Rα (CD127) and the cytokine common γ-chain (CD132). This 
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receptor is expressed, and can be measured, on the cell-surface of a majority of 
differentiated CD8+ T-cells, but it is transiently down-regulated during proliferation in 
response to antigenic stimuli [73].  
 
Other important cell-surface markers expressed by different immune cells including T-
cells are e.g. CD95, which is a receptor involved in modulation of T-cell activation and 
in pro- and anti-apoptotic signaling cascades [74]. CD117 is a cell-surface receptor 
expressed on different types of hematopoietic progenitor cells and plays a role in cell 
survival, proliferation, and differentiation [75].  
 
1.2 MULTIMERS 
1.2.1 Structure 
Due to too low avidity between individual MHC complex 
and TCRs, it is not possible to visualize individual MHC-
TCR interactions directly in ex vivo sampled blood 
specimens by flow cytometry. Instead, multimerization 
of the MHC molecules allows for simultaneous binding 
of multiple MHC molecules to TCRs on the cell-surface 
of T-cells, thereby increasing the avidity. Multimers (e.g. 
tetramers, pentamers and dextramers) are flow cytometry 
reagents initially developed in 1996 [44] that are used for 
detecting antigen-specific T-cells ex vivo. They consist of 
at least 4 soluble MHC class I molecules presenting the 
same peptide-epitope, linked together via a fluorescent 
labeled linker (e.g. streptavidin, avidin or dextran) (Figure 6). Today, multimers exist 
commercially for most of the common ‘Caucasian’ and ‘Asian’ MHC class I alleles. 
However, we do not have sufficient access to soluble MHC class I molecules covering 
the most frequent ‘African’ MHC class I alleles. 
 
1.2.2 Function 
Multimers provide an efficient way to identify, enumerate, visualize and sort antigen-
specific CD8+, and to a lesser extent CD4+, T-cells directly in blood, in frozen 
peripheral blood mononuclear cells (PBMCs) or in tissue samples [44, 76, 77]. They 
can be combined with other cell-surface markers to derive important information about 
the phenotype, effector functions, activation status, homing capacity, proliferation and 
Figure 6. Multimer 
recognition of an antigen-
specific T-cell. 
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apoptosis of T-cells [78]. The reagents can be used for measuring antigen-specific 
response in infection and after vaccination. They can also be utilized for sorting and 
purification of antigen-specific T-cells for subsequent analysis, therapeutic transfer [79] 
or TCR analysis. One advantage of the use of multimers is the fact that it is possible to 
assess T-cell frequencies without any in vitro manipulation [44]. The major drawback 
with this method is that it does not provide any direct evidence of function, e.g. killing 
capacity or cytokine production. However, MHC class I multimeric analysis can be 
combined with analysis of cytokine production, although the currently applied 
protocols may not allow accurate estimation of MHC class I-TCR interactions, since 
detection of intracellular cytokines requires fixation and permeabilization of the cell-
membrane and this may result in lower frequency of multimer positive events. 
 
1.3 TUBERCULOSIS  
1.3.1 The bacterium 
M.tb was isolated and identified as the causative agent of TB by Robert Koch in 1882. 
M.tb is a large rod-shaped bacterium (2–4 µm in length and 0.2–0.5 µm in width) 
belonging to the genus Mycobacterium. M.tb is a facultative intracellular parasite that 
usually infects human macrophages. The generation time is long, usually 15–20 h, 
defining it as a slow-growing pathogen. The bacteria are classified as acid-fast due to 
their complex cell-walls impermeability to a number of dyes. The cell-wall consists of 
peptidoglycan and complex lipids (e.g. mycolic acids, acyl glycolipids and sulfolipids) 
and is an important virulence factor of the bacteria [80]. M.tb has circular chromosomes 
about 4 200 000 nucleotides long containing about 4 000 genes [81]. Many of these 
genes are still unknown, although intensive research has been performed since the 
genomic sequence was revealed in 1998 [82]. Among the proteins with identified 
function, an unusual high amount participates in the fatty acid metabolism. Another 
distinctive feature of the mycobacterial genome is the large group of unrelated proteins 
containing specific repeats of proline (P) and glutamic acid (E) (PE and PPE proteins) 
[83] .  
  
1.3.2 The disease 
M.tb is able to cause disease in almost all organs in the human body (e.g. lung, central 
nervous system, the bones and the joints). However, since the bacteria are mainly 
transmitted via the airborne route, pulmonary TB is the most prevalent form of disease. 
Extrapulmonary TB is most common in immunosuppressed individuals, e.g. those 
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infected by HIV and young children. Not all individuals exposed to aerosols 
contaminated with M.tb acquire infection, usually repeated contact is required. An 
infection starts with the aspiration of bacteria to the pulmonary alveoli where they 
infect resident macrophages. Macrophages phagocyte the bacteria, but instead of being 
degraded in the hostile environment of the phagolysosomes that normally form and 
degrade phagocytosed pathogens, M.tb stops the fusion of the phagosomic and 
lysosomic compartments, thereby creating an immune privilege niche were they can 
survive and replicate [84]. Early during infection, professional APCs like alveolar 
macrophages, monocyte-derived macrophages and DCs take up the bacteria, 
subsequently DCs travel to the draining lymph nodes and present M.tb antigens to 
naïve T-cells [85]. The T-cells become activated and afterwards home to the infected 
lung tissues where they orchestrate the formation of granulomatous structures, 
together with neutrophils and monocytic cells, which may contain the M.tb bacilli. In 
a majority of cases, the host immune system is able to control the initial infection and 
keep the bacteria in a dormant, non-replicating state. In this state, the infected 
individuals are neither sick nor infectious, i.e. they are carrying latent TB. During a 
lifetime there is in general a 10 % risk of reactivation of latent TB into active disease. 
The only vaccine used today against M.tb is the M.bovis-derived Bacillus Calmette 
Guérin (BCG) originating from 1921. Billions of people have been vaccinated with this 
vaccine but its efficacy is questioned, as it seems to give limited effect against 
pulmonary TB in adult individuals, dependent on the geographic regions and previous 
exposure of environmental mycobacteria [86]. 
 
1.3.3 Adaptive immune responses to M.tb 
As previously mentioned, M.tb is an intracellular pathogen; therefore the adaptive 
immune response is primary directed by Th1 cytokines (e.g. IL-2, IFN-γ and TNF-α), 
i.e. cell-mediated. Many different T-cell subsets have been shown to be important, 
including CD4+ T-cells [4], CD8+ T-cells [5] and unconventional and regulatory T-
cells. However, anti-M.tb directed humoral immune responses have recently gained 
increased interest in protection against mycobacteria, both regarding modulation of the 
cell-mediated immune response as well as in a direct protecting role against M.tb 
infection [87, 88]. Another kind of adaptive immune response against M.tb infection is 
the IL-17 mediated Th17 response [89], associated with recruitment and activation of 
neutrophils [90].  
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1.3.4 Genetic variability and immune responses against M.tb 
The outcome of infectious diseases depends on a delicate balance between host (e.g. 
genetic variants of factors in the immune system and different MHC alleles) and 
pathogen-derived factors (e.g. virulence factors and escape mutations), as well as other 
external factors like co-existing diseases and environmental factors (including stress, 
malnutrition, poverty and helminth infections).  
 
Host-derived factors, differences in ethnicity and certain MHC class I alleles have been 
shown to be important for the specific T-cell responses in many disease settings, 
including hepatitis B [91], hepatitis C [92] and HIV [93]. Considering M.tb 
susceptibility, associations between specific lineages of M.tb and certain populations 
indicate local host-pathogen co-adaptation [94]. More recently, increasing evidence of 
host-derived gene polymorphisms (e.g. IFN-γ [95], DC-SIGN, vitamin D receptor [96], 
toll like receptor variants [97] and nitric oxide synthase [98]) affecting TB 
susceptibility have been identified. In addition, different studies have linked individual 
MHC class II molecules to increased or decreased susceptibility to M.tb infection in 
different population cohorts (e.g. HLA-DR2 in Indian and Russian populations [99, 
100] and HLA-DR4 in the Italian population [101]). Despite the fact that no significant 
association between MHC class I alleles and M.tb susceptibility has been found, inter-
allelic variations in the MHC class I locus may still have impact on immune recognition 
due to their possibility to present different peptide repertoires and thereby influencing 
immune recognition by antigen-specific T-cells.  
 
1.3.5 M.tb epitopes 
The sequencing of the entire H37Rv M.tb reference genome [82] opened many new 
possibilities to identify molecularly defined protein targets for CD4+ and CD8+ T-cell 
epitopes. Yet, a majority of the identified T-cell epitopes derived from M.tb proteins 
originates from a limited set of well-studied targets, like the early expressed virulence 
factors ESAT-6, CFP10, TB10.4 and the Ag85complex [102-104], as well as the very 
abundant PE and PPE family proteins [105]. 
 
1.3.6 Genetic diversity in M.tb 
The genetic diversity in the M.tb genome between different bacterial strains seems to be 
quite low, but some differences (insertions, deletions and point mutations) have been 
identified [106]. However, these variations may have both phenotypical and 
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immunological impact, e.g. by changing the ability of the infected individuals to induce 
a cellular immune response [107, 108]. Most variations in the TB genome reside in 
non-essential genes and it has previously been shown that human T-cell epitopes show 
little sequence variability in proteins derived from M.tb. This seems to hold true for 
many proteins, except for the small immunogenic protein TB10.4 being one exception 
[109].  
 
1.3.7 Immunogenic M.tb proteins  
1.3.7.1 TB10.4 (Rv0288) 
TB10.4 (Rv0288) (also known as ESAT-6-like 
protein esxH, CFP7) is a well-studied early 
expressed and secreted TB virulence factor of 10 
kDa (96 amino acids). It consists of two major α-
helixes and forms a dimer with TB9.8 (Rv0287) 
(Figure 7). It is expressed in both the vaccine 
strain BCG as well as in virulent M.tb strains 
[110]. TB10.4 is part of the 6 kDa early 
secretory antigenic target (ESAT-6) gene family 
which encodes a number of secreted 
immunodominant molecules such as TB10.3 and 
TB12.9 [103]. A few CD8+ T-cell epitopes 
have previously been described for this protein 
[111, 112]. TB10.4 is also a component in 
several novel TB-vaccine candidates [113]. 
 
1.3.7.2 Ag85B (Rv1886c) 
The 30 kDa (325 amino acids) Ag85B (Rv1886c) (also known as α antigen or MPT59) 
is the most abundant protein expressed by M.tb. The secondary structure of the protein 
consists of 7 α-helixes encircling a central parallel β-sheet (Figure 8). It is both a 
secreted and cell-wall associated protein that seems to be primarily expressed during 
the early stages of infection and is expressed both by M.tb and by the M.bovis-derived 
vaccine strain BCG as well as in mycobacteria other than tuberculosis (MOTT). The 
protein is one of three closely related mycolyl transferase molecules (the others are 
Ag85A and Ag85C) contributing to cell-wall biosynthesis synthesis by catalyzing the 
transfer of the fatty acid mycolate from one trehalose monomycolate to another. This 
Figure 7. Structure of M.tb protein 
TB10.4 (left part) and TB9.8 (right part). 
Adapted from PDB file 2KG7 [176].
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results in trehalose 6,60-
dimycolate and free trehalose 
[114]. The protein has been 
shown to be among the most 
potent antigens identified 
[115] and is a major target of 
human T-cell responses to 
M.tb [104], and it is also part 
of many novel TB-vaccine 
candidates [113, 116].  
 
1.3.7.3 ESAT-6 (Rv3875) 
ESAT-6 (esxA, Rv3875) is a 
95 amino acid long M.tb-
derived protein which forms a dimer with another M.tb protein: CFP10 [117]. It 
belongs to the RD1 region which is only present in a limited number of mycobacterial 
species including M.tb and e.g. M. marinum and M. kansasii, but is absent in BCG and 
many other mycobacterial species [118]. This makes it an interesting diagnostic marker 
for differentiating between vaccinated and M.tb infected individuals [119]. It belongs to 
an extended family (~23 members) of small (~100 amino acids) proteins from which 
many CD4 and CD8 T-cell epitopes have already been identified and most patients 
infected with M.tb recognize the antigen. The protein also contributes to M.tb 
pathogenicity, as deletion of the gene leads to attenuation of the bacteria [120]. ESAT-6 
is expressed early in infection and contributes to apoptosis of macrophages and lung 
epithelial cells, thereby permitting cell-to cell spread of M.tb. In addition, 
immunomodulatory effects on macrophages, like perturbation of intracellular signaling 
pathways affecting antigen-presentation and cytokine production have been reported 
[121-123]. 
 
1.3.7.4 Glycosyl transferases and cyclopropane fatty acid synthase  
Non-secreted M.tb-proteins like glycosyl transferase (1) (Rv2958c), glycosyl 
transferase (2) (Rv2957) and the cyclopropane fatty acid synthase (CFA synthase) 
(Rv0447c) are expressed predominantly in slow growing bacteria such as 
mycobacteria. The glycosyl transferases are enzymes involved in glycosylation steps 
downstream of branched lipids like phenolic glycolipid (which are associated with M.tb 
Figure 8. Structure of M.tb protein Ag85B. 
Adapted from PDB file 1F0N [177].
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hypervirulence [124]), and esters like glycosylated p-hydroxybenzoic acid methyl 
esters biosynthesis [125] (products that seems to be associated with resistance to 
intracellular killing by macrophages [126]). The CFA-synthase belongs to a group of 
enzymes involved in the creation of important components for making the cell-wall 
impermeable (i.e. cyclopropanation of the mycolic acids) [127].  
 
The proteins are known to be immunogenic, since they have been identified to be 
targets for humoral responses [128] and HLA-class II presentation [129], as well as T-
cells responses measured in whole blood assays, assessing CD4+ and CD8+ T-cell 
responses [130]. In addition, these proteins are mainly expressed by slow growing 
bacteria and might therefore show a different pattern of immunogenicity compared to 
the early expressed M.tb antigens.  
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2 AIM OF THE THESIS 
 
 
• Identification of MHC class I binding epitopes in the TB protein TB10.4 using 
a panel of Caucasian MHC class I molecules. 
 
• Construct monomers for some of the most frequent ‘African’ MHC class I 
alleles: HLA-A*30:01, A*30:02, A*68:01, B*58:01 and C*07:01. 
 
• Construct a peptide binding assay and identify MHC-peptide binding epitopes 
for the M.tb-associated antigens TB10.4, Ag85B and ESAT-6. 
 
• Further characterize the binding properties of the identified peptide binding 
epitopes from TB10.4, Ag85B and ESAT-6. 
 
• Construct MHC class I multimers presenting M.tb protein-derived epitopes 
(TB10.4, Ag85B, ESAT-6, glycosyl transferase 1, glycosyl transferase 2 and 
cyclopropane fatty acid synthase) to enumerate MHC class I restricted CD8+ T-
cells. 
 
• Employ the multimers for characterization of M.tb-specific T-cells directly in 
blood obtained from patients with M.tb infection with different ethnic 
background (Caucasian, Asian and African). 
 
• Evaluate the number of existing T-cell epitopes from M.tb-derived proteins. 
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3 METHODOLOGICAL DEVELOPMENT 
3.1 PATIENTS WITH PULMONARY TB 
In this thesis, PBMCs from patients with active pulmonary TB were used to enumerate 
and characterize antigen-specific T-cells in different settings. These patients had 
different genetic background and originated from different geographic regions. In 
Paper I we used T-cells from Caucasian patients originating from Mainz, Germany, in 
Paper IV we used cells from TB patients from South Korea and in Papers II and III we 
used cells from patient with a sub-Saharan African background, originating from two 
different sites in South Africa (Pretoria and Cape Town). 
 
3.2 DEVELOPMENT OF NOVEL MATERIALS AND METHODS 
3.2.1 African MHC class I alleles 
Today, the most frequently expressed MHC class I alleles in a Caucasian and Asian 
population exist commercially, but since different African population groups have a 
very diverse expression of MHC class I alleles, the lack of commercially available tools 
for many of the most common alleles in this area represents a major problem to directly 
enumerate T-cells in blood from patient with TB. In order to overcome this challenge, 
we constructed and produced some of the most common African MHC class I alleles 
[14, 131] recombinantly for Papers II and III (e.g. HLA-A*30:01, A*30:02, A*68:01, 
B*58:01 and C*07:01). This represents a major part of this thesis. 
 
3.2.2 Recombinant MHC class I molecules 
In addition to the above listed ‘African’ MHC class I molecules, several previously 
described MHC class I alleles (e.g. HLA-A*02:01, A*24:02 and B*07:02) were 
produced recombinantly during this thesis and used in Papers II, III and IV. Bacterial 
expression vectors (pET24d+ and pHN1) containing the nucleotide sequences for the 
soluble part of the heavy chain of the MHC class I alleles and the light-chain β2m 
were either newly cloned or contributed by Beckman Coulter, San Diego, CA. All 
recombinant MHC class I molecules (‘African’ and ‘Caucasian/Asian’) were 
produced as previously described [132]. In summary, heavy and light chains were 
produced in Escherichia coli Bl21 DE3 pLys as inclusion bodies and solubilized in an 
8 M urea buffer, pH 6.5, and folded to correct trimeric structure in a pH 8.0 Tris-
EDTA-arginine buffer together with allele-specific candidate peptides (Table 2). 
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Folded MHC class I-peptide monomers were biotinylated using the enzyme BirA. 
The biotinylated monomers were affinity purified using an avidin column. 
 
Table 2. 
The MHC class I molecules included in this thesis and their control peptides. 
 
Allele Control Peptide Original protein 
A*01:01 EVDPIGHLY MAGE-A3 
A*02:01 FLPSDFFPSV HBV CORE 
A*03:01 KVFPCALINK Consensus peptide modified at position 5 
A*11:01 AVFDRKSDAK EBV EBNA 3B 
A*24:02 RYLKDQQLL HIV env 
A*30:01 KTKDIVNGL F-actin capping protein beta 
A*30:02 KIQNFRVYY HIV-integrase 
A*68*01 KTGGPIYKR Influenza virus nucleoprotein 
B*07:02 TPRVTGGGAM  CMV pp65 
B*08:01 EIYKRWII HIV p24 
B*15:01 AMKGLPIRY DENGUE VIRUS NS3 
B*58:01 IAMESIVIW HIV RT 
C*07:01 KYFDEHYEY CDC28 protein 
 
3.2.3 Peptide binding assay 
In Paper I, a commercially available peptide binding assay (iTOPIA, Beckman 
Coulter, San Diego, CA) was used for the most common ‘Caucasian’ MHC class I 
alleles. A similar peptide binding assay was constructed for several MHC class I alleles 
(A*02:01, A*24:02, A*30:01, A*30:02, A*68:01, B*07:02, B*58:01 and C*07:01) and 
used in Papers II and III. Briefly, ninety-six-well plates were first coated with 
biotinylated bovine serum albumin, followed by avidin and biotinylated monomer 
(0.5 µg/ml). During the first step of the assay, the monomer-coated plates were 
stripped of the placeholder peptide leaving the heavy chain free to reassociate with an 
added candidate peptide after addition of β2m. Peptide binding was detected as 
fluorescence, after 18 h of incubation at 21 °C with a conformational antibody (either 
fluorescein isothiocyanate [FITC]-conjugated anti-HLA-A, -B and -C [A*02, A*24, 
A*68, B*07, B*58 and C*07] [Beckman Coulter, San Diego, USA] or anti-HLA-A30 
[One Lambda Inc, Canoga Park, USA]) (Figure 9). The binding of each candidate 
peptide was compared with the binding of an appropriate control peptide (Table 2). 
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This assay was not only used for assessing peptide binding, but also for assessing 
peptide-MHC affinity and dissociation rate (Papers I–III). The dissociation rate was 
measured as a t1/2 value, which is defined as the time point when 50 % of the initial 
peptide concentration has dissociated from the MHC-peptide molecule complexes. The 
measurements took place after incubating the refolded MHC molecules at 37 °C at 
eight different time points (0 h, 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 6 h and 8 h). Affinity was 
measured incubating titrated peptide concentrations (10-4 to 10-9 M) overnight and then 
calculating the peptide quantity needed to achieve 50 % binding saturation. 
 
3.2.4 Multimers 
In this thesis (Papers I–IV), 62 M.tb-derived multimers (tetramers and dextramers) 
were constructed, of which 50 were never previously described (12 were described in 
[104, 133-137]) (Table 3). They were either purchased (Beckman Coulter, San Diego, 
USA and Immudex, Copenhagen, Denmark) or constructed in our laboratory as 
previously described [44]. A particular focus was made to construct M.tb multimers 
based on MHC class I alleles not commercially available and common in an African 
population (e.g. HLA-A*30:01, B*58:01 and C*07:01).  
 
 
Figure 9. Schematic structure of the peptide binding assay. In the first step, both the placeholder 
peptide and β2m are stripped away using an acidic buffer. By subsequent addition of a candidate peptide 
as well as new β2m, the trimeric complex is able to refold if the candidate peptide binds to the selected 
MHC class I allele. Formation of the trimeric complex can be measured using a conformation-dependent 
antibody.  
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Table 3. 
List of constructed multimers for this thesis, including epitope-derived protein, epitope sequence and the 
restricting MHC class I allele.  
 
Antigen Sequence Allele Study Antigen Sequence Allele Study 
Rv02882-10 SQIMYNYPA A*02:01 I Rv0447c331-337 KYIFPGGLL A*24:02 III, IV 
Rv02883-11 QIMYNYPAM A*11:01 I Rv0447c396-404 RMWELYLAY A*30:02 III 
Rv02883-11 QIMYNYPAM A*30:01 II, III Rv1886c77-85 YLLDGLRAQ A*02:01 III 
Rv02883-11 QIMYNYPAM A*30:02 II, III Rv1886c100-108 WYYQSGLSI A*24:02 III 
Rv02884-12 IMYNYPAML A*02:01 I, III, IV Rv1886c110-118 MPVGGGSSF B*07:02 III 
Rv02884-12 IMYNYPAML A*24:02 I, III, IV Rv1886c133-141 QTYKWETFL B*58:01 III 
Rv02884-12 IMYNYPAML A*30:02 II, III Rv1886c140-146 FLTSELPQW A*24:02 III 
Rv02884-12 IMYNYPAML B*07:02 I Rv1886c145-153 LPQWLSANR A*68:01 III 
Rv02885-13 MYNYPAMLG A*24:02 III Rv1886c183-191 FIYAGSLSA A*02:01 III, IV 
Rv02885-13m3 MYNYPTMLD A*24:02 III Rv1886c184-192 IYAGSLSAL A*24:02 III, IV 
Rv028810-18 AMLGHAGDM A*02:01 III Rv1886c184-192 IYAGSLSAL B*07:02 III 
Rv028810-18m2 AMLDHAGDM A*02:01 III Rv1886c200-208 GPSLIGLAM B*07:02 III 
Rv028811-19 MLGHAGDMA A*02:01 III Rv1886c237-245 IPKLVANNT B*07:02 III 
Rv028811-19m1 MLDHAGDMA A*02:01 III Rv1886c239-247 KLVANNTRL A*02:01 III, IV 
Rv028820-28 GYAGTLQSL A*24:02 I Rv1886c241-249 VANNTRLWV A*30:01 III 
Rv028843-51 WQGDTGITY B*15:01 I Rv1886c241-249 VANNTRLWV A*30:02 III 
Rv028850-58 TYQAWQAQW A*24:02 I Rv1886c242-250 ANNTRLWVY C*07:01 III 
Rv028854-62 WQAQWNQAM B*15:01 I Rv1886c307-315 WGAQLNAMK A*68:01 III 
Rv028860-68 QAMEDLVRA A*02:01 I Rv295726-34 SIIIPTLNY A*02:01 III, IV 
Rv028861-69 AMEDLVRAY A*03:01 I Rv2957137-145 LVYGDVIMR A*68:01 III 
Rv028861-69 AMEDLVRAY A*30:02 II, III Rv2957183-191 PYNLRYRVL A*24:02 III, IV 
Rv028865-73 LVRAYHAMS A*30:01 II, III Rv2957249-257 IVLVRRWPK A*30:01 III 
Rv028870-78 HAMSSTHEA A*68:01 III Rv2958c22-30 AAPEPVARR A*68:01 III 
Rv028878-86 ANTMAMMAR A*11:01 I Rv2958c110-118 KYIAADRKI A*24:02 III, IV 
Rv028878-86 ANTMAMMAR A*68:01 III Rv2958c138-146 SARLAGIPY A*30:02 III 
Rv028881-89 MAMMARDTA B*07:02 I Rv2958c288-296 ALADLPVTV A*02:01 III, IV 
Rv028882-90 AMMARDTAE B*07:02 I Rv387528-36 LLDEGKQSL A*02:01 III, IV 
Rv028883-91 MMARDTAEA A*02:01 I Rv387550-58 AYQGVQQKW A*24:02 III, IV 
Rv028883-91 MMARDTAEA B*08:01 I Rv387564-72 ELNNALQNL A*24:02 III, IV 
Rv0447c31-39 AASAAIANR A*68:01 III Rv387582-90 AMASTEGNV A*02:01 III, IV 
Rv0447c110-118 VLAGSVDEL A*02:01 III, IV Rv387582-90 AMASTEGNV A*30:02 III 
 
 
3.2.5 Flow cytometry 
The multimers were used in flow-cytometric experiments together with other cell-
surface markers (Table 4). Panel 1 was used in Paper I, while panel 2 was used in 
Papers II, III and IV. In Paper IV, panels 3 and 4 were used. 
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Table 4. 
List of cell-surface markers used for defining T-cell phenotypes and effector functions. 
 
Panel 1 – Small multimer panel Panel 2 – Large multimer panel Panel 3 – ’Stem-cell’ markers Panel 4 – ICS 
CD3 CD3 CD3 CD3 
CD4 CD4 CD4 CD4 
CD8 CD8 CD8 CD8 
Multimer CD45RA CD45RA IL-17 
  CCR7 CCR7 IL-2 
  CD127 CD95 IFN-γ 
  CD107a CD117 TNF-α 
  Multimer(s) Multimer(s)  
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4 RESULTS AND DISCUSSION 
The main aim of this thesis was the identification of T-cell epitopes restricted via MHC 
class I molecules common in different ethnical population groups, and subsequent 
analysis of the nature of the antigen-specific T-cells that recognize them. Therefore, we 
have been studying M.tb-derived epitopes on several levels including: 1) peptide-MHC 
interaction, 2) T-cell epitope recognition and 3) phenotype and effector functions of the 
antigen-specific T-cells.  
 
4.1 MHC CLASS I BINDING EPITOPE IDENTIFICATION 
Many human T-cell epitopes originating from M.tb-derived proteins have been 
identified until today. We have, by using the immune epitope database [45], evaluated 
more than 800 human epitopes. By investigating the epitope-derived protein, we could 
see that all the M.tb-derived epitopes that have been identified thus far originated from 
only 170 out of an estimated total of ~4 000 proteins, i.e. only 4 % of the M.tb genome 
[81] (Paper V). This leaves most of the genome still unexplored regarding T-cell 
epitopes. For the majority of the 170 epitope-containing proteins, only a single epitope 
has been found. For other protein-derived virulence factors, a significant number (>20) 
of epitopes have already been identified (e.g. Ag85A, Ag85B, TB10.4, ESAT-6 and 
Cfp10) (Paper V). Although quite a number of epitopes have been identified, a bias and 
a lack of proper knowledge still exist regarding the nature of many of these epitopes. In 
line with previous findings regarding the nature of human M.tb epitopes [138], we have 
pinpointed challenging areas concerning M.tb epitope identification: 1) A majority of 
the epitopes are MHC class II restricted CD4+ T-cell epitopes based on the length (>11 
amino acids), 2) information is missing about the disease/vaccination status 
(active/latent M.tb and/or BCG vaccination) of the individual from which an immune 
response is originating, 3) information about the epitope-derived M.tb strain is not 
known, 4) information is missing about the function and expression pattern of the 
epitope-derived protein and, finally, 5) information about the restricting allele is in 
many cases either missing or it represents one of the alleles common in the Caucasian 
population groups, such as HLA-A*02:01. The last bias is particularly problematic, 
since high TB burden exists in many parts of the world, where the population groups 
express predominantly other MHC class I allotypes than HLA-A*02:01, for example 
populations in sub-Saharan Africa and Southeast Asia [1].  
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4.1.1.1 TB10.4-, Ag85B- and ESAT-6-derived MHC class I binding epitopes 
Due to the limited knowledge of M.tb-derived epitopes binding to a broad variety of 
human MHC class I alleles, we aimed at identifying novel immunogenic epitopes 
recognized by individuals with different genetic backgrounds. Therefore, Papers I–III 
reported the identification of a large amount of novel peptide binding epitopes from 
several different M.tb-derived proteins (TB10.4, Ag85B and ESAT-6) to a diverse 
panel of MHC class I molecules (HLA-A*01:01, A*02:01, A*03:01, A*11:01, 
A*24:02, A:30:01, A*30:02, A*68:01, B*07:02, B*08:01, B*15:01, B*58:01 and 
C*07:01) covering the most common alleles in Caucasian, Asian and African 
population groups [14]. In Paper I, we identified 53 binding epitopes in TB10.4 for 8 
MHC class I alleles common in the Caucasian population (Figure 10). In Paper II, we 
continued to study binding epitopes from the same M.tb-derived protein in association 
with two of the most common sub-Saharan African MHC class I alleles (HLA-A*30:01 
Figure 10. Identified binding epitopes in the M.tb-derived protein TB10.4. Binding of different 
epitopes to a panel of 13 different MHC class I molecules; HLA-A*01:01 (light purple), A*02:01 (red), 
A*03:01(apricot), A*11:01 (pink), A*24:02 (dark purple), A*30:01 (orange), A*30:02 (dark green), 
A*68:01 (middle blue), B*07:02 (light blue), B*08:01 (light green), B*15:01 (dark blue), B*58:01 (grey) 
and C*07:01 (black) (Papers I–III ).  
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and A*30:02). In this study, we could identify 25 novel epitopes, including the first 
M.tb-associated epitopes binding to HLA-A*30:02 (Figure 10). In Paper III, we 
identified 29 additional TB10.4 epitopes associating with three other ‘African’ alleles 
(HLA-A*68:01, B*58:01 and C*07:01) (Figure 10) as well as 292 peptide epitopes 
originating from Ag85B and 40 epitopes from ESAT-6 associating with HLA-A*02:01, 
A*24:02, A*30:01, A*30:02, A*68:01, B*07:02, B*58:01 or C*07:01. The 30 epitopes 
associating with HLA-C*07:01 were the first ever identified disease-related epitopes 
for this allele.  
 
4.1.1.2 Difference in MHC class I restricted peptide binding repertoires  
As has previously been reported [139, 140], a discrepancy in the peptide binding 
capacity exists between different MHC class I alleles (Table 5). We found that some of 
the alleles included in these studies exhibited a broad (A*30:02, A*02:01 and 
A*24:02), some an intermediate (A*68:01 and B*58:01) or some a restricted (B*07:02 
and C*07:01) peptide binding pattern. Particularly interesting is the fact that although 
the difference is only four amino acids [13], there is a remarkable discrepancy in the 
binding between the two alleles belonging to the A*30 family (i.e. A*30:01/A*30:02) 
(Paper II), in part due to structural constrains, electrostatic charges and 
hydrophobicities within the binding pockets responsible for the binding repertoire [20].  
 
Table 5. 
Number of identified epitopes restricted by selected MHC class I molecules for the M.tb-derived proteins 
TB10.4, Ag85B and ESAT-6.  
 
  Number of Epitopes 
Allele TB10.4 Ag85B ESAT-6 Total 
A*01:01 2 – – 2 
A*02:01 17 57 11 85 
A*03:01 2 – – 2 
A*11:01 3 – – 3 
A*24:02 10 41 2 53 
A*30:01 3 8 0 11 
A*30:02 22 78 21 121 
A*68:01 11 29 3 43 
B*07:02 7 25 0 32 
B*08:01 0 – – 0 
B*15:01 12 – – 12 
B*58:01 14 29 2 45 
C*07:01 4 25 1 30 
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For the majority of the most common MHC class I alleles, the peptide binding motif 
has been determined. Based on similar preferences for specific amino acids at certain 
positions, the MHC class I alleles have been divided into groups called supertypes 
[141]. In this thesis (Papers I–III), we identified epitopes matching perfectly with their 
assigned motif but also epitopes that matched only partially or did not match at all with 
the assigned MHC-peptide binding motif. For example, the very well-studied alleles 
HLA-A*02:01 and A*24:02 matched quite well concerning actual peptide binding data 
and peptide-MHC class I motifs (Papers I and III) [22, 142]. Also for the alleles HLA-
A*68:01, B*07:02 and B*58:01, the majority of identified epitopes correlate at least 
partly with their assigned motif [142-144]. On the other hand, for alleles with less well-
studied or disputable motifs (e.g. HLA-A*30:01), the majority of epitopes does not 
match the assigned motifs at all [145, 146]. Therefore, the data indicates that A*3001 
may, as has previously been suggested, be able to use different arrangements of 
primary and secondary anchor residues [27]. For the allele HLA-A*30:02, we could 
identify a very broad peptide binding repertoire with diverse amino acids (hydrophobic, 
charged and polar) at the anchor positions, indicating that HLA-A*3002 utilizes 
multiple secondary anchor residues in the C- and N-terminal regions and may 
therefore show a promiscuous binding motif. However, the allele also seems to prefer 
tyrosine (Y) residues at P9 (Papers II–III, all epitopes with Y at P9 bound strongly) 
which is in line with the determined peptide motif [145]. For C*07:01, no motif exists 
to our knowledge, but based on the identified binding epitopes (Paper III) we are able 
to identify a preference for tyrosine or phenylalanine at P9.  
 
4.1.1.3 Promiscuous MHC class I binding epitopes 
Another very interesting discovery documented in Papers I–III was the frequently 
occurring ‘cross-binding’ of epitopes to different MHC class I alleles. The epitope 
TB10.44-12 is, for example, recognized by no less than 9/13 tested MHC class I alleles 
including both HLA-A, -B and -C alleles (Papers I–III), indicating a potential very 
broad immune recognition (Figure 10). Promiscuous binding has previously been 
identified for other pathogens like HIV, HPV and tumor associated antigens [140, 147, 
148] and is likely to have clinical implications. In the field of vaccine design, the fact 
that a single peptide epitope is presented by a diverse repertoire of MHC alleles might 
facilitate the development of peptide vaccines, as fewer epitopes are needed to cover 
large population cohorts. On the other hand, a narrower focus on a few selected 
epitopes might facilitate immune escape variants, as described for viral pathogens (e.g. 
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HIV [149] and HCV [150]) although epitope-variations have only rarely been seen in 
M.tb thus far [109].  
 
4.2 CHARACTERIZATION OF THE PEPTIDE-MHC BINDING 
PROPERTIES 
The affinity and dissociation rate (off-rate) of a peptide-MHC complex determine the 
time-frame in which an epitope is available for T-cell priming on the cell-surface and 
for target recognition (in the effector phase) of the immune response. In Papers I–III, 
we determined these two parameters for most of the identified binding epitopes and 
could identify a range of intra-allelic differences (different peptides bound different to 
the same MHC class I allele) as well as inter-allelic differences (same peptides bound 
differently to different alleles).  
 
The stability (ED50 value) generally ranged between 800 µM and 5 nM, which is in 
line with previous studies [104, 139], and we could see no significant variations 
between the different MHC class I alleles (Papers I–III). The dissociation rate, on the 
other hand, ranged between 0.1 h and 27 h and varied considerably between different 
MHC class I alleles. HLA-A*02:01 showed the broadest range of off-rate with 
peptides dissociating very rapidly (~0.3 h) as well as very slowly (27 h). Generally, 
peptides that bound to the alleles with few identified binding epitopes (e.g. HLA-
A*30:01, B*07:02 and C*07:01) tended to dissociate more rapidly, a fact that might 
originate from intrinsic structural features of the allotype (Papers I–III). A more 
restricted binding repertoire, in addition to a faster dissociation rate, might suggest a 
disadvantage in immune recognition in individuals with certain MHC class I allelic 
background. However, a fast peptide off-rate seems to be able to be counter-balanced 
by a high affinity, as described in Paper III.  
 
4.3 ENUMERATION OF ANTIGEN-SPECIFIC T-CELLS 
Prior to this thesis, only a limited number of MHC class I M.tb-specific multimers had 
been utilized in different settings (active-latent TB, children, HIV co-infected 
individuals and vaccine settings). We evaluated them in Paper V and could detect that 
the vast majority of the multimers were constructed using the common ‘Caucasian’ 
MHC class I allele: HLA-A*02:01 [14]. In addition, we could detect a bias towards a 
limited set of epitope-derived proteins, like the Ag85 proteins (Rv3804, Rv1886c and 
Rv2905c) [104, 133-135, 137, 151-153], ESAT-6 (Rv3875) [135, 137], 16kDaAg 
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(Rv2031c) [137], Hsp65 (Rv0440) [137], 19kDaAg (Rv3763) [135, 154], probable 
membrane protein (Rv1490) [137] and lgt (Rv1614) [137], despite the fact that M.tb 
contains around 4 000 different proteins [81].  
 
4.3.1.1 Detection of antigen-specific T-cells using novel MHC class I multimers 
In order to gauge new immunogenic epitopes derived from M.tb antigens, we 
enumerated and characterized the antigen-specific T-cell repertoire in patients with 
acute pulmonary TB. A broad array of (62) novel M.tb-specific multimers (Papers I–
IV) was constructed, in order to test T-cells in peripheral blood from these patients.  
 
Generally, we could identify a low, yet clearly detectable, broad recognition of several 
co-dominant epitopes derived from different M.tb proteins in the peripheral circulation 
of most patients with acute pulmonary TB, independent of their genetic background 
(Caucasians 0–2.1 % [Paper I], Africans 0–3.9 % [Papers II–III] and Asians 0–6.5 % 
[Papers IV]). The frequencies of antigen-specific CD8+ T-cells varied between the 
recognized epitopes (0–6.5 %), with the majority being recognized at least in some 
patients with acute pulmonary M.tb infection. This broad recognition is in line with 
another recent publication identifying multimer-specific novel A*02:01-restricted 
epitopes from another set of novel M.tb-derived proteins [155]. However, we could also 
identify some epitopes that appeared to be associated with higher T-cell frequencies, 
including the ESAT-6-derived epitope ELNNALQNL restricted by HLA-A*24:02 
and the Ag85B-derived epitope KLVANNTRL restricted by A*02:01 (Paper III–IV). 
In Paper I (but not in Paper III due to too few HLA-B epitopes included) we were 
able to observe a predominantly HLA-B restricted T-cell response in line with 
previous studies on TB [104, 156], as well as in viral diseases like HIV [157], EBV 
[158] and CMV [159]. An HLA-B restricted dominant response might be linked to 
either differences at the MHC expression level on APCs and/or differences in the 
TCR repertoire that is available to recognize the respective MHC class I-peptide 
complex. Another reason for HLA-B dominance may be a selective interference of 
pathogens with HLA-A processing or up-regulation of HLA-B alleles [156]. 
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4.3.1.2 MHC class I allotype and epitope-derived protein might influence T-cell 
recognition 
When a large cohort of different MHC class I restricted multimers was used to 
characterize the M.tb-specific CD8+ T-cell response (Paper III), allele-specific 
recognition patterns could be identified. This observation also held true when 
combining the frequencies of antigen-specific T-cells detected in Papers I–IV. As can 
be seen in Figure 11A, HLA-A*03:01 and A*24:02 as well as HLA-B*07:02 and 
B*08:01 restricted epitopes were generally detected by a higher proportion of CD8+ T-
cells than for example HLA-A*02:01, A*30:02, A*68:01 and B*15:01 restricted 
epitopes. Certain immunodominant epitopes might of course skew these results to a 
A 
B 
Figure 11. Combined detection of multimer positive CD8+ T-cells (Papers I–IV) stratified by 
restricting MHC class I allotype (A) and epitope-derived protein (B). 
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certain extent, but the fact that we have included up to 16 different epitopes restricted 
by the same allotype strengthens the observed differences. 
 
In addition to allele-specific differences in the frequencies of antigen-specific T-cell 
recognition, differences based on epitope-derived antigens could be identified in 
Papers I–IV. For example within the group of well-characterized early expressed M.tb 
antigens (TB10.4, Ag85B and ESAT-6), we could detect higher frequencies of antigen-
specific T-cells recognizing ESAT-6-derived epitopes (0.69 %) compared to TB10.4 
(0.26 %) and Ag85B (0.27 %). However, we believe that this result is biased by the 
strong recognition of the immunodominant epitope A24-ESAT-6ELNNALQNL. While 
comparing antigen-specific recognition to other (not yet reported) M.tb-derived 
antigens, such as two glycosyl transferases and cyclopropane fatty acid synthase, 
expressed predominantly in slow-growing mycobacteria, additional differences in 
frequencies of antigen-specific T-cells could be seen. The glycosyl-transferase 2 
(Rv2957) was for example more strongly recognized (0.48 %) than some of the 
previously well-studied immunodominant antigens (TB10.4 and Ag85B) [103] (Figure 
11B). 
 
4.4 CHARACTERIZATION OF THE ANTIGEN-SPECIFIC T-CELLS 
4.4.1.1 Phenotypic characterization 
In Papers II–IV, we also examined the phenotype and effector functions of the antigen-
specific CD8+ T-cells. The phenotype of CD8+ T-cells can be defined by the usage of 
the cell-surface markers CD45RA and CCR7. M.tb antigen-specific T-cells have 
previously been described to predominantly belong to different T-cell compartments 
including terminally differentiated compartments CD45RA+CCR7- [137], memory 
compartments (CD45RA-) [104, 152] as well as precursor like compartments 
(CD45RA+CCR7+). In this thesis, we could detect that a majority of the antigen-
specific CD8+ T-cells belongs to a compartment with a precursor-like phenotype, 
despite the different genetic background of the M.tb-infected individuals. This is in line 
with a number of previous studies which have identified a large frequency of M.tb-
specific or BCG reactive T-cells in both adults and children expressing a ‘naïve’-like 
phenotype [134, 160, 161]. Reasons for the high number of antigen-experienced cells 
with a precursor-like phenotype might include an increase in lymphopoiesis in 
patients with TB as well as a recycling of terminally differentiated antigen-
experienced cells to the precursor CD8+ T-cell compartment by re-expression of 
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CCR7, as has been suggested in the field of HIV [162]. Another explanation might be 
that these cells belong to a stem-cell memory compartment, as we suggest in Paper 
IV, based on expression of CD45RA and CCR7, along with the stem-cell markers 
CD95 and c-kit (CD117). This has previously been seen in the context of other viral 
diseases and in the context of tumor antigens, where recent studies have identified 
‘naïve’-like T-cell populations based on the expression of the cell-surface markers 
CD45RA, CCR7, and CD127 as well as memory and stem-cell like markers such as 
CD95 and/or c-kit. It is hypothesized that these T-cells represent a long-lived subset of 
antigen-experienced multipotent cells [163, 164] 
 
The frequency of antigen-specific T-cells that reside in a certain phenotypic 
compartment varies, as could be seen in Paper III, in association with the restricting 
MHC class I allele. Restriction by certain alleles like HLA-A*30 and C*07 lead to 
higher proportions of antigen-specific, terminally differentiated CD8+ T-cells, which 
may be important in controlling the infectious disease [5]. In addition, T-cells restricted 
via these allotypes showed increased expression of the degranulation marker CD107a, 
indicating increased cytotoxic functionality. The nature of the epitope-derived M.tb 
protein also influences the phenotype of the antigen-specific CD8+ T-cells. For 
example, in Paper IV we could detect a significant difference in the proportion of cells 
belonging to the terminally differentiated and precursor compartments between T-cells 
recognizing epitopes derived from TB10.4, Ag85B and ESAT-6 as compared to 
epitopes derived from the glycosyl transferases and cyclopropane fatty acid synthase. 
This might be due to differences in expression pattern (secreted/intracellular retained 
and/or expressed early in infection/during active/latent infection) of the antigenic 
proteins influencing immune recognition and thereby the priming event of specific 
CD8+ T-cells.  
 
4.4.1.2 Expression of survival markers and effector functions 
As expected, CD107a is up-regulated on antigen-specific T-cells independent of the 
restricting MHC class I allele and independent of the presented epitope (Papers II–IV), 
indicating an increased cytolytic function of these antigen-experienced cells. However, 
as previously mentioned, T-cells restricted by certain MHC class I allotypes show 
higher expression of this cell-surface marker as well as expression of the IL7-Rα T-cell 
survival marker (Paper III).  
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In Paper IV, we investigated the frequencies of antigen-specific cytokine-producing 
cells (IL-17, IL-2, IFN-γ and TNF-α) and were able to detect a low, yet clearly 
detectable, cytokine production (0–0.2 % of the CD8+ T-cells) in response to 
stimulation with the M.tb antigens TB10.4 and ESAT-6. The frequencies of cytokine-
producing cells were similar or lower as compared to cytokine-producing M.tb-specific 
CD8+ T-cells identified in other studies [165-167]. In addition, we were able to 
compare the frequencies of cytokine-producing CD8+ T-cells to the frequencies of 
multimer-specific CD8+ T-cells in response to the same M.tb-derived antigen (TB10.4 
and ESAT-6). Although the cytokine production was measured in response to 
overlapping peptides covering protein we were often able to detect higher frequencies 
of CD8+ T-cells specific to a single epitope (derived from the same protein) using 
multimers. The fact that we were able to detect higher frequencies by ex vivo 
identification of multimer reactive T-cells (probably cytotoxic based on high CD107a 
expression) has previously been reported in the context of HIV, where the CD8+ T-
cells tend to exhibit either of these functions (cytokine production or cytotoxicity), but 
rarely both [168]. These results imply that functional T-cell assays based solely on 
detection of Th1 cytokines might underestimate the number of M.tb reactive T-cells. 
 
The biological consequence concerning T-cell effector functions needs to be further 
studied. Of note, the PBMCs analyzed in our studies derived from patients with active 
TB and may therefore not represent the potential breadth of a strong protective CD8+ 
T-cell response, due to decreased CD8+ T-cell effector functionality in active TB [137]. 
 
4.5 VARIANT M.TB EPITOPES 
The genome of M.tb is regarded as rather constant, with only minor polymorphism 
[169]. However, recently more frequent strain-to-strain variations have been reported. 
Most polymorphisms have been identified in non-essential genes, yet also in essential 
genes and in human T-cell epitopes from immunogenic M.tb proteins. One of the M.tb-
derived proteins with the highest frequency of single nucleotide polymorphism (SNP), 
compared to its size, is the well-studied immunogenic protein TB10.4 [109]. In Paper 
III, we compared MHC class I binding and subsequent CD8+ T-cell recognition of 
TB10.4 epitopes from the reference genome H37Rv with epitopes from SNP-
containing clinical isolates [170]. We showed: 1) Alteration of an epitope 
predominantly reduces its binding to the assigned MHC class I allele based on either an 
increased dissociation rate or a decreased affinity between the peptide and MHC 
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complex. 2) Variations in epitope sequences affect T-cell recognition. 3) Epitope 
variability leads to alteration of the phenotype and expression of cell-surface markers 
like CD107a and CD127 of the antigen-specific CD8+ T-cells. 4) Different T-cell 
repertoires seem to recognize the wild-type and variant epitopes (Paper III). 
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5 GENERAL CONCLUSIONS 
  
• The usage of recombinant MHC class I molecules is a fast and objective way of 
identifying novel T-cell epitopes, which can be confirmed by the usage of 
multimers. 
 
• Small differences in the peptide binding cleft between different MHC class I 
allotypes (e.g. HLA-A*30:01 and A*30:02) can give rise to completely 
different peptide binding repertoires. 
 
• Promiscuous binding of M.tb-derived epitopes to many different MHC class I 
allotypes (including both HLA-A, -B and -C alleles) occurs and the epitopes 
give rise to T-cell responses restricted via different alleles.  
 
• With the novel epitopes derived from M.tb proteins, it is possible to construct 
M.tb multimers and subsequently enumerate antigen-specific T-cell responses 
ex vivo. In combination with usage of other cell markers it is also possible to 
determine the phenotype and possible effector functions of M.tb-specific T-
cells. 
 
• The frequencies of antigen-specific T-cells recognizing different M.tb epitopes 
are usually quite low but broad. Non-immunodominant recognition of several 
different epitopes can be seen in blood from most patients with active 
pulmonary TB. 
 
• The antigen-specific T-cell responses against M.tb tend to be HLA-B restricted 
but some immunodominant HLA-A epitopes could also be detected.  
 
• The 1) restricting MHC class I allotype, 2) epitope-derived protein and 3) 
specific peptide sequence (including SNPs) seem to influence many levels of 
antigen-specific T-cell responses, including peptide-MHC binding, TCR 
recognition as well as effector functionality and the phenotype of the antigen-
specific T-cells. 
 
• A high proportion of M.tb-specific CD8+ T-cells express a precursor-like 
phenotype based on expression of the cell-surface markers CD45RA and 
CCR7. This might be due to cells that belong to a compartment of antigen-
experienced memory cells expressing both precursor markers (CD45RA/CCR7) 
and ‘stem-cell markers’ (CD95/c-kit). 
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6 FUTURE PERSPECTIVES 
 
We have developed novel MHC class I allotypes including previously not 
commercially available alleles (e.g. HLA-A*30:01, B*58:01 and C*07:01) with the 
hope that these might be useful not only in association with M.tb but also in other 
disease settings (infectious as well as malignant). Some alleles have previously been 
connected with protection or association with certain diseases. Expression of HLA-
A*30:01 has, for example, been associated with increased risk of type 1 diabetes [171] 
as well as with severity of plasmodium falciparum mediated malaria [172], B*58:01 
has been associated with HIV elite controllers [173] as well as for increased risk of 
certain drug hypersensibility reactions [174]. HLA-C*07 alleles have, on the other 
hand, been associated with predisposition for Graves’ disease [175]. Very little is 
reported on the peptide repertoire of this allele and it would in general be interesting 
and important to discover additional C*07:01 restricted immunogenic epitopes in 
different disease settings and also to determine its peptide binding motif and 
subsequently identify and analyze additional antigen-specific T-cells.  
 
Only a small fraction of the identified M.tb-derived binding epitopes identified in these 
studies were validated by multimer analysis as actually being CD8+ T-cell epitopes. 
Therefore, we have identified a reservoir of putative epitopes that could be selected for 
M.tb multimer construction, based on the binding characteristics (affinity and 
dissociation rate) determined within this study. Such multimers could then be used in 
future studies in which identification of M.tb-specific T-cells could provide additional 
value. It would also help to visualize a very broad array of T-cell responses restricted 
by a high number of different MHC class I molecules. 
 
Regarding the 62 M.tb-specific multimers used in these studies, additional verification 
needs to be made in larger patient cohorts. Yet, we hope to be able to validate the use of 
M.tb-specific MHC class I multimers in studies of the specific immune response in 
M.tb-infected patients, and to link these markers with clinical endpoints. Examples 
include gauging vaccine take of novel anti-M.tb vaccine candidates and testing novel 
diagnostic markers (e.g. ESAT-6 responses, independent of cytokine production) in 
well defined cohorts. 
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The immunogenicities of glycosyl transferases and cyclopropane fatty acid synthase 
were previously discovered by our group in the context of MHC class II presentation as 
well as for antibody recognition [128, 129], and we have in these studies also been able 
to demonstrate CD8+ T-cell recognition. It is of importance to further characterize the 
ability of these antigens to elicit a strong CD8+ T-cell response, since they are not 
secreted (like the majority of the previously characterized M.tb-derived antigens) but 
intracellularly retained. In the future, we would like to address other issues concerning 
these M.tb-derived proteins, e.g. expression patterns and their potential use as vaccine 
candidates.  
 
Other questions that arose during this thesis that we would like to examine include: 
- To decipher if the allele-specific recognition, phenotypic and cytolytic 
expression pattern identified in these studies in association with M.tb antigens 
are specific for this disease, or if it could be extrapolated to other infectious 
disease settings as well.  
- To further characterize the antigen-specific CD8+ T-cells with a precursor like 
phenotype based on expression of the cell-surface markers CD45RA, CCR7, 
CD95 and c-kit. It would also be of interest to study why those obviously 
antigen-experienced cells express these markers. What is the impact of these 
variations in vaccinated individuals that encounter an infection with an M.tb 
variant and what are their functions; is there an association with the biologically 
and clinically relevant endpoints (i.e. long-term immune memory formation)? 
- To validate the multimers expressing the altered TB10.4-derived epitopes in 
different population cohorts and further characterize the subsets of specific 
CD8+ T-cells recognizing the original and altered epitopes. 
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